Earnings call Caplin Point posted an 11% YoY revenue growth and 21.6% PAT growth in H1 FY26, with EBITDA margin expanding to 34.1%. The company maintained strong cash reserves and guided for continued ...
Caplin Point Laboratories makes a range of branded and generic pharmaceuticals such as antibiotics, non-steroidal anti-inflammatory drugs, ophthalmic, pain management, and anti-ulcer products. Founded ...
Earnings call Caplin Point Laboratories reported a 10.6% YoY revenue growth and 20.5% PAT increase in Q3 FY26, with EBITDA margin expanding to 38.5%. Management reaffirmed a consolidation phase ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results